We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
Vaccine recipient claims he suffered side effect of severe blood clot
How pension funds’ investments have impacted the London Stock Exchange
Growth cap on UK’s health service branded drugs bill will rise to 4% from 2027
German group says prospective blockbuster asundexian failed to demonstrate efficacy
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Regulator authorises treatment for sickle cell disease and beta thalassaemia
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
US and UK regulators say diabetes medication showed ‘significant’ weight loss benefits
German group is examining spinning off its crop sciences or consumer health businesses in effort to restore fortunes
Preliminary probe looks into financial communications around 2017 launch of group’s blockbuster drug Dupixent
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Biotech blames weaker US sales after lowering full-year forecast
Danish group has expanded manufacturing capacity but says demand will continue to outstrip supply
First jab for respiratory syncytial virus powers sales at UK drugmaker
Domestically made products like syringes currently cost more than those produced in China
Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer
UK Biobank’s records of 500,000 people promise breakthroughs in diseases and ageing
French pharma group announces consumer unit split and increased R&D investment
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Sector has been critical of government after sharp rise in clawback tax
International Edition
